DK0833643T3 - Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme - Google Patents

Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme

Info

Publication number
DK0833643T3
DK0833643T3 DK96920607T DK96920607T DK0833643T3 DK 0833643 T3 DK0833643 T3 DK 0833643T3 DK 96920607 T DK96920607 T DK 96920607T DK 96920607 T DK96920607 T DK 96920607T DK 0833643 T3 DK0833643 T3 DK 0833643T3
Authority
DK
Denmark
Prior art keywords
pct
monosodium salt
anhydrous
alendronate
formulations
Prior art date
Application number
DK96920607T
Other languages
English (en)
Inventor
Gerald S Brenner
Drazen Ostovic
Earl R Oberholtzer Jr
J Eric Thies
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23862592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0833643(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0833643T3 publication Critical patent/DK0833643T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK96920607T 1995-06-06 1996-06-03 Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme DK0833643T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46914395A 1995-06-06 1995-06-06
PCT/US1996/008284 WO1996039149A1 (en) 1995-06-06 1996-06-03 Anhydrous alendronate monosodium salt formulations

Publications (1)

Publication Number Publication Date
DK0833643T3 true DK0833643T3 (da) 2005-05-30

Family

ID=23862592

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96920607T DK0833643T3 (da) 1995-06-06 1996-06-03 Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme

Country Status (11)

Country Link
US (1) US5849726A (da)
EP (1) EP0833643B1 (da)
JP (1) JP3344726B2 (da)
AT (1) ATE289199T1 (da)
AU (1) AU5886096A (da)
CA (1) CA2221417C (da)
DE (1) DE69634357T2 (da)
DK (1) DK0833643T3 (da)
ES (1) ES2236737T3 (da)
PT (1) PT833643E (da)
WO (1) WO1996039149A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6148396A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
BR9712683A (pt) 1996-10-28 1999-10-19 Nyomed Imaging A S Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6392071B1 (en) 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
SK2482001A3 (en) 1998-08-27 2002-01-07 Teva Pharma Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1702924A3 (en) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6963008B2 (en) 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001030788A1 (en) * 1999-10-26 2001-05-03 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use
CA2410880C (en) * 2000-05-31 2009-03-03 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
BRPI0511530A (pt) 2004-05-24 2008-01-02 Procter & Gamble formas de dosagem de bisfosfonatos
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
EP1865928A1 (en) 2005-03-17 2007-12-19 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JPH11511041A (ja) * 1995-06-06 1999-09-28 メルク エンド カンパニー インコーポレーテッド 整形外科的埋め込み装置の無菌性動揺を防止するビスホスホネートセメント組成物

Also Published As

Publication number Publication date
DE69634357T2 (de) 2006-01-12
EP0833643B1 (en) 2005-02-16
EP0833643A1 (en) 1998-04-08
US5849726A (en) 1998-12-15
JPH11506116A (ja) 1999-06-02
CA2221417C (en) 2002-04-30
PT833643E (pt) 2005-06-30
CA2221417A1 (en) 1996-12-12
ATE289199T1 (de) 2005-03-15
AU5886096A (en) 1996-12-24
DE69634357D1 (de) 2005-03-24
JP3344726B2 (ja) 2002-11-18
WO1996039149A1 (en) 1996-12-12
ES2236737T3 (es) 2005-07-16
EP0833643A4 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
PT833643E (pt) Formulacoes de sal anidro de alendronato
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
DE69417733D1 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
IL104109A0 (en) Pharmaceutical compositions containing aldenorate for treating periodontal diseases
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
PT1039900E (pt) Agentes terapeuticos
DK0476066T3 (da) Antiviralt præparat indeholdende 3-azido-2,3-dideoxy-5-methylcytidin
SE9402001D0 (sv) Pyridylbisphosphonates for use as a therapeutical agent
PL371264A1 (en) Method for the treatment of bone disorders
DK0769945T3 (da) Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
CO4920257A1 (es) Metodo para disminuir el riesgo de fracturas vertebrales y no vertebrales
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця